Your browser does not support the NLM PubReader view. Go to this page to see a list of supported browsers or return to the regular view. |
Agency for Healthcare Research and Quality (US), Rockville (MD)
Knudsen AB, Rutter CM, Peterse EFP, et al. Colorectal Cancer Screening: An Updated Decision Analysis for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 May. (Technical Report, No. 202s.) Appendix 13, Efficiency Status and Efficiency Ratios With Estimated Colorectal Cancer Deaths.
| Strategy | Efficient frontier status, by model and benefit variable | |||||
|---|---|---|---|---|---|---|
| SimCRC | CRC-SPIN | MISCAN | ||||
| LYG | CRC deaths averted | LYG | CRC deaths averted | LYG | CRC deaths averted | |
| COL 55-70, 15 | E | E | E | E | E | E |
| COL 55-70, 10 | -- | NE | NE | NE | NE | NE |
| COL 50-70, 15 | NE | E | NE | E | E | NE |
| COL 55-85, 15 | -- | NE | -- | -- | -- | NE |
| COL 45-70, 15 | E | -- | E | NE | NE | -- |
| COL 55-75, 10 | -- | NE | -- | -- | -- | E |
| COL 50-80, 15 | -- | NE | -- | NE | NE | NE |
| COL 55-85, 10 | -- | -- | -- | -- | -- | NE |
| COL 50-70, 10 | -- | NE | -- | NE | E | NE |
| COL 45-75, 15 | NE | E | NE | E | NE | NE |
| COL 45-70, 10 | E | NE | E | NE | E | -- |
| COL 50-80, 10 | -- | NE | -- | NE | NE | E |
| COL 45-75, 10 | E | E | E | E | E | NE |
| COL 55-75, 5 | -- | -- | -- | -- | -- | NE |
| COL 45-85, 10 | NE | E | NE | E | NE | NE |
| COL 55-80, 5 | -- | -- | -- | -- | -- | NE |
| COL 50-70, 5 | -- | -- | -- | -- | NE | NE |
| COL 55-85, 5 | -- | -- | -- | -- | -- | NE |
| COL 50-75, 5 | -- | -- | -- | -- | NE | NE |
| COL 50-80, 5 | -- | -- | -- | -- | -- | E |
| COL 50-85, 5 | -- | -- | -- | -- | -- | NE |
| COL 45-70, 5 | NE | NE | E | NE | E | NE |
| COL 45-75, 5 | E | NE | E | E | E | NE |
| COL 45-80, 5 | E | E | E | E | E | E |
| COL 45-85, 5 | E | E | E | E | E | E |
COL – colonoscopy; E – strategy is efficient; NE – strategy is near efficient; -- indicates strategy is dominated and does not meet the criteria for near efficiency.
Note: Strategies that were dominated with both measures across all models are not shown. Analyses assume an increased population risk of colorectal cancer based on an incidence rate ratio comparing colorectal cancer incidence among 20- to 44-year-olds in 2012-2016 vs 1975-1979 of 1.19.
| Strategy | Efficient frontier status, by model and benefit variable | |||||
|---|---|---|---|---|---|---|
| SimCRC | CRC-SPIN | MISCAN | ||||
| LYG | CRC deaths averted | LYG | CRC deaths averted | LYG | CRC deaths averted | |
| FIT 55-70, 3 | E | E | E | E | E | E |
| FIT 55-75, 3 | -- | E | -- | E | E | E |
| FIT 50-70, 3 | E | -- | E | NE | NE | -- |
| FIT 55-70, 2 | -- | -- | -- | NE | NE | -- |
| FIT 55-80, 3 | -- | E | -- | E | NE | E |
| FIT 45-70, 3 | E | -- | E | -- | NE | -- |
| FIT 50-75, 3 | -- | NE | -- | NE | E | -- |
| FIT 55-85, 3 | -- | NE | -- | NE | NE | E |
| FIT 55-75, 2 | -- | -- | -- | NE | NE | -- |
| FIT 50-80, 3 | -- | E | -- | E | E | NE |
| FIT 50-70, 2 | -- | -- | -- | NE | NE | -- |
| FIT 45-75, 3 | E | NE | NE | NE | NE | -- |
| FIT 50-85, 3 | -- | E | -- | NE | NE | NE |
| FIT 55-80, 2 | -- | NE | -- | E | -- | NE |
| FIT 45-80, 3 | NE | NE | NE | NE | E | -- |
| FIT 45-70, 2 | NE | -- | E | NE | -- | -- |
| FIT 50-75, 2 | -- | -- | -- | NE | NE | -- |
| FIT 45-85, 3 | NE | E | -- | E | NE | -- |
| FIT 55-85, 2 | -- | NE | -- | NE | -- | E |
| FIT 55-70, 1 | -- | -- | -- | NE | -- | -- |
| FIT 50-80, 2 | -- | NE | -- | NE | E | NE |
| FIT 45-75, 2 | E | -- | E | NE | NE | -- |
| FIT 50-85, 2 | -- | NE | -- | NE | NE | E |
| FIT 45-80, 2 | E | NE | E | E | E | -- |
| FIT 55-75, 1 | -- | -- | -- | NE | -- | -- |
| FIT 45-85, 2 | NE | E | NE | E | E | NE |
| FIT 55-80, 1 | -- | -- | -- | -- | -- | NE |
| FIT 50-75, 1 | -- | -- | -- | NE | NE | -- |
| FIT 55-85, 1 | -- | -- | -- | -- | -- | E |
| FIT 45-70, 1 | NE | -- | E | NE | -- | -- |
| FIT 50-80, 1 | -- | NE | -- | NE | NE | NE |
| FIT 45-75, 1 | E | -- | E | NE | NE | -- |
| FIT 50-85, 1 | -- | NE | -- | NE | NE | E |
| sDNA-FIT 45-80, 3 | -- | -- | -- | NE | -- | -- |
| sDNA-FIT 45-70, 2 | -- | -- | NE | -- | -- | -- |
| FIT 45-80, 1 | E | NE | E | NE | E | NE |
| sDNA-FIT 45-85, 3 | -- | -- | -- | NE | -- | -- |
| FIT 45-85, 1 | E | E | E | E | E | E |
| sDNA-FIT 50-85, 2 | -- | -- | -- | -- | -- | NE |
| sDNA-FIT 45-75, 2 | NE | -- | NE | NE | -- | -- |
| sDNA-FIT 45-80, 2 | NE | NE | NE | NE | NE | -- |
| sDNA-FIT 45-85, 2 | NE | NE | NE | NE | NE | NE |
| sDNA-FIT 45-70, 1 | NE | -- | NE | -- | -- | -- |
| sDNA-FIT 50-80, 1 | -- | -- | -- | -- | -- | NE |
| sDNA-FIT 50-85, 1 | -- | -- | -- | -- | -- | NE |
| sDNA-FIT 45-75, 1 | NE | -- | E | NE | NE | -- |
| sDNA-FIT 45-80, 1 | E | NE | E | NE | NE | NE |
| sDNA-FIT 45-85, 1 | E | E | E | E | E | E |
FIT – fecal immunochemical test with a cutoff for positivity of 20 μg of hemoglobin per g of feces; sDNA-FIT – multitarget stool DNA test (stool DNA test with a fecal immunochemical test); E – strategy is efficient; NE – strategy is near efficient; -- indicates strategy is dominated and does not meet the criteria for near efficiency.
Note: Strategies that were dominated with both measures across all models are not shown. Analyses assume an increased population risk of colorectal cancer based on an incidence rate ratio comparing colorectal cancer incidence among 20- to 44-year-olds in 2012-2016 vs 1975-1979 of 1.19.
| Strategy | Efficient frontier status, by model and benefit variable | |||||
|---|---|---|---|---|---|---|
| SimCRC | CRC-SPIN | MISCAN | ||||
| LYG | CRC deaths averted | LYG | CRC deaths averted | LYG | CRC deaths averted | |
| SIG 55-70, 10 | E | E | E | E | E | E |
| SIG 55-75, 10 | -- | NE | -- | E | -- | E |
| SIG 50-70, 10 | -- | E | -- | E | E | NE |
| SIG 45-70, 10 | E | NE | E | NE | NE | -- |
| SIG 55-85, 10 | -- | NE | -- | NE | -- | NE |
| SIG 55-70, 5 | -- | NE | -- | NE | NE | NE |
| SIG 50-80, 10 | -- | NE | -- | NE | NE | NE |
| SIG 55-75, 5 | -- | NE | -- | NE | -- | NE |
| SIG 45-75, 10 | NE | E | E | E | NE | NE |
| SIG 50-70, 5 | -- | NE | -- | NE | E | NE |
| SIG 45-85, 10 | -- | NE | NE | E | NE | NE |
| SIG 55-80, 5 | -- | NE | -- | -- | -- | E |
| SIG 55-85, 5 | -- | -- | -- | -- | -- | NE |
| SIG 50-75, 5 | -- | NE | -- | NE | NE | NE |
| SIG 45-70, 5 | E | NE | E | NE | E | -- |
| SIG 50-80, 5 | -- | NE | -- | NE | NE | E |
| SIG 50-85, 5 | -- | NE | -- | NE | NE | E |
| SIG 45-75, 5 | E | E | E | NE | E | NE |
| SIG 45-80, 5 | E | E | E | E | E | NE |
| SIG 45-85, 5 | E | E | E | E | E | E |
SIG – sigmoidoscopy; E – strategy is efficient; NE – strategy is near efficient; -- indicates strategy is dominated and does not meet the criteria for near efficiency.
Note: Strategies that were dominated with both measures across all models are not shown. Analyses assume an increased population risk of colorectal cancer based on an incidence rate ratio comparing colorectal cancer incidence among 20- to 44-year-olds in 2012-2016 vs 1975-1979 of 1.19.
| Strategy | Efficient frontier status, by model and benefit variable | |||||
|---|---|---|---|---|---|---|
| SimCRC | CRC-SPIN | MISCAN | ||||
| LYG | CRC deaths averted | LYG | CRC deaths averted | LYG | CRC deaths averted | |
| SIG+FIT 55-70, 10_2 | E | E | E | E | E | E |
| SIG+FIT 55-70, 10_1 | -- | -- | -- | NE | NE | NE |
| SIG+FIT 55-75, 10_2 | -- | E | -- | E | NE | NE |
| SIG+FIT 50-70, 10_2 | NE | NE | NE | NE | E | -- |
| SIG+FIT 55-80, 10_2 | -- | NE | -- | NE | NE | E |
| SIG+FIT 50-75, 10_2 | -- | E | -- | E | E | NE |
| SIG+FIT 45-70, 10_2 | E | -- | E | NE | NE | -- |
| SIG+FIT 55-85, 10_2 | -- | NE | -- | NE | -- | E |
| SIG+FIT 55-75, 10_1 | -- | -- | -- | NE | -- | NE |
| SIG+FIT 50-70, 10_1 | -- | -- | -- | NE | NE | -- |
| SIG+FIT 50-80, 10_2 | -- | E | -- | NE | NE | NE |
| SIG+FIT 55-80, 10_1 | -- | -- | -- | NE | -- | NE |
| SIG+FIT 50-85, 10_2 | -- | NE | -- | NE | NE | E |
| SIG+FIT 45-75, 10_2 | E | NE | E | NE | NE | NE |
| SIG+FIT 55-85, 10_1 | -- | -- | -- | -- | -- | NE |
| SIG+FIT 50-75, 10_1 | -- | -- | -- | NE | NE | NE |
| SIG+FIT 45-80, 10_2 | E | E | E | E | E | NE |
| SIG+FIT 45-70, 10_1 | NE | -- | NE | NE | NE | -- |
| SIG+FIT 50-80, 10_1 | -- | -- | -- | NE | NE | NE |
| SIG+FIT 45-85, 10_2 | NE | E | NE | E | NE | NE |
| SIG+FIT 50-85, 10_1 | -- | NE | -- | NE | NE | E |
| SIG+FIT 45-75, 10_1 | E | NE | E | NE | NE | NE |
| SIG+FIT 45-80, 10_1 | E | NE | E | NE | E | NE |
| SIG+FIT 45-85, 10_1 | E | E | E | E | E | E |
SIG – sigmoidoscopy; FIT – fecal immunochemical test with a cutoff for positivity of 20 μg of hemoglobin per g of feces; E – strategy is efficient; NE – strategy is near efficient; -- indicates strategy is dominated and does not meet the criteria for near efficiency.
Note: Strategies that were dominated with both measures across all models are not shown. Analyses assume an increased population risk of colorectal cancer based on an incidence rate ratio comparing colorectal cancer incidence among 20- to 44-year-olds in 2012-2016 vs 1975-1979 of 1.19.
| Strategy | Efficient frontier status, by model and benefit variable | |||||
|---|---|---|---|---|---|---|
| SimCRC | CRC-SPIN | MISCAN | ||||
| LYG | CRC deaths averted | LYG | CRC deaths averted | LYG | CRC deaths averted | |
| CTC 55-70, 10 | E | E | E | E | E | E |
| CTC 55-75, 10 | -- | NE | -- | E | -- | E |
| CTC 50-70, 10 | -- | E | -- | NE | E | -- |
| CTC 45-70, 10 | E | -- | E | NE | -- | -- |
| CTC 55-70, 5 | -- | -- | -- | NE | NE | NE |
| CTC 55-85, 10 | -- | -- | -- | NE | -- | E |
| CTC 50-80, 10 | -- | NE | -- | NE | NE | NE |
| CTC 55-75, 5 | -- | -- | -- | NE | NE | NE |
| CTC 45-75, 10 | NE | E | NE | E | -- | -- |
| CTC 50-70, 5 | -- | NE | -- | NE | E | -- |
| CTC 55-80, 5 | -- | -- | -- | NE | NE | E |
| CTC 45-85, 10 | -- | NE | NE | E | -- | -- |
| CTC 55-85, 5 | -- | -- | -- | NE | -- | E |
| CTC 50-75, 5 | -- | NE | -- | NE | E | -- |
| CTC 45-70, 5 | E | NE | E | NE | NE | -- |
| CTC 50-80, 5 | -- | NE | -- | NE | NE | NE |
| CTC 50-85, 5 | -- | NE | -- | NE | NE | E |
| CTC 45-75, 5 | E | NE | E | NE | E | -- |
| CTC 45-80, 5 | E | E | E | E | E | NE |
| CTC 45-85, 5 | E | E | E | E | E | E |
CTC – computed tomographic colonography; E – strategy is efficient; NE – strategy is near efficient; -- indicates strategy is dominated and does not meet the criteria for near efficiency.
Note: Strategies that were dominated with both measures across all models are not shown. Analyses assume an increased population risk of colorectal cancer based on an incidence rate ratio comparing colorectal cancer incidence among 20- to 44-year-olds in 2012-2016 vs 1975-1979 of 1.19.
| Strategy | Efficiency ratio (Δ COL / Δ CRC deaths averted) | ||
|---|---|---|---|
| SimCRC | CRC-SPIN | MISCAN | |
| COL 55-70, 15 | -- | -- | -- |
| COL 55-70, 10 | N/A* | 423* | N/A* |
| COL 50-70, 15 | 258 | 227 | N/A* |
| COL 55-85, 15 | 659* | Dominated | 529* |
| COL 45-70, 15 | Dominated | 2115* | Dominated |
| COL 55-75, 10 | 725* | Dominated | 429 |
| COL 50-80, 15 | 346* | 545* | 515* |
| COL 55-85, 10 | Dominated | Dominated | 844* |
| COL 50-70, 10 | 380* | 579* | 712* |
| COL 45-75, 15 | 320 | 423 | 13793* |
| COL 45-70, 10 | 480* | 2029* | Dominated |
| COL 50-80, 10 | 2418* | 693* | 526 |
| COL 45-75, 10 | 625 | 801 | 2712* |
| COL 55-75, 5 | Dominated | Dominated | 1099* |
| COL 45-85, 10 | 1277 | 2341 | 1539* |
| COL 55-80, 5 | Dominated | Dominated | 7788* |
| COL 50-70, 5 | Dominated | Dominated | 6254* |
| COL 55-85, 5 | Dominated | Dominated | 5972* |
| COL 50-75, 5 | Dominated | Dominated | 1838* |
| COL 50-80, 5 | Dominated | Dominated | 1489 |
| COL 50-85, 5 | Dominated | Dominated | 3178* |
| COL 45-70, 5 | 31880* | 4594* | 2374* |
| COL 45-75, 5 | 3172* | 3258 | 2431* |
| COL 45-80, 5 | 2817 | 3392 | 1495 |
| COL 45-85, 5 | 4268 | 8623 | 3351 |
COL – colonoscopy; CRC – colorectal cancer; N/A – not applicable; the efficiency ratio cannot be calculated because there is no efficient strategy with fewer colorectal cancer deaths averted; -- indicates the default strategy (i.e., the strategy requiring the fewest colonoscopies and averting the fewest colorectal cancer deaths).
Near efficient (i.e., within 0.75 colorectal cancer deaths averted per 1000 of the efficient frontier).
Note: Strategies that were dominated in all 3 models are not shown. Analyses assume an increased population risk of colorectal cancer based on an incidence rate ratio comparing colorectal cancer incidence among 20- to 44-year-olds in 2012-2016 vs 1975-1979 of 1.19.
| Strategy | Efficiency ratio (Δ COL / Δ CRC deaths averted) | ||
|---|---|---|---|
| SimCRC | CRC-SPIN | MISCAN | |
| FIT 55-70, 3 | -- | -- | -- |
| FIT 55-75, 3 | 37 | 54 | 35 |
| FIT 50-70, 3 | Dominated | 425* | Dominated |
| FIT 55-70, 2 | Dominated | 69* | Dominated |
| FIT 55-80, 3 | 42 | 58 | 36 |
| FIT 50-75, 3 | 52* | 89* | Dominated |
| FIT 55-85, 3 | 59* | 75* | 46 |
| FIT 55-75, 2 | Dominated | 73* | Dominated |
| FIT 50-80, 3 | 57 | 73 | 826* |
| FIT 50-70, 2 | Dominated | 104* | Dominated |
| FIT 45-75, 3 | 84* | 216* | Dominated |
| FIT 50-85, 3 | 59 | 85* | 123* |
| FIT 55-80, 2 | 166* | 82 | 122* |
| FIT 45-80, 3 | 167* | 133* | Dominated |
| FIT 45-70, 2 | Dominated | 272* | Dominated |
| FIT 50-75, 2 | Dominated | 159* | Dominated |
| FIT 45-85, 3 | 75 | 99 | Dominated |
| FIT 55-85, 2 | 151* | 102* | 86 |
| FIT 55-70, 1 | Dominated | 210* | Dominated |
| FIT 50-80, 2 | 178* | 110* | 271* |
| FIT 45-75, 2 | Dominated | 116* | Dominated |
| FIT 50-85, 2 | 123* | 115* | 119 |
| FIT 45-80, 2 | 115* | 103 | Dominated |
| FIT 55-75, 1 | Dominated | 186* | Dominated |
| FIT 45-85, 2 | 104 | 113 | 210* |
| FIT 55-80, 1 | Dominated | Dominated | 257* |
| FIT 50-75, 1 | Dominated | 1296* | Dominated |
| FIT 55-85, 1 | Dominated | Dominated | 171 |
| FIT 45-70, 1 | Dominated | 934* | Dominated |
| FIT 50-80, 1 | 531* | 317* | 344* |
| FIT 45-75, 1 | Dominated | 249* | Dominated |
| FIT 50-85, 1 | 339* | 282* | 174 |
| sDNA-FIT 45-80, 3 | Dominated | 369* | Dominated |
| FIT 45-80, 1 | 241* | 217* | 308* |
| sDNA-FIT 45-85, 3 | Dominated | 317* | Dominated |
| FIT 45-85, 1 | 223 | 216 | 294 |
| sDNA-FIT 50-85, 2 | Dominated | Dominated | 466* |
| sDNA-FIT 45-75, 2 | Dominated | 335* | Dominated |
| sDNA-FIT 45-80, 2 | 390* | 305* | Dominated |
| sDNA-FIT 45-85, 2 | 2427* | 1019* | 1049* |
| sDNA-FIT 50-80, 1 | Dominated | Dominated | 2068* |
| sDNA-FIT 50-85, 1 | Dominated | Dominated | 3337* |
| sDNA-FIT 45-75, 1 | Dominated | 1276* | Dominated |
| sDNA-FIT 45-80, 1 | 1384* | 851* | 2699* |
| sDNA-FIT 45-85, 1 | 1066 | 783 | 1295 |
COL – colonoscopy; CRC – colorectal cancer; FIT – fecal immunochemical test with a cutoff for positivity of 20 μg of hemoglobin per g of feces; sDNA-FIT – multitarget stool DNA test (stool DNA test with a fecal immunochemical test); -- indicates the default strategy (i.e., the strategy requiring the fewest colonoscopies and averting the fewest colorectal cancer deaths).
Near efficient (i.e., within 0.75 colorectal cancer deaths averted per 1000 of the efficient frontier).
Note: Strategies that were dominated in all 3 models are not shown. Analyses assume an increased population risk of colorectal cancer based on an incidence rate ratio comparing colorectal cancer incidence among 20- to 44-year-olds in 2012-2016 vs 1975-1979 of 1.19.
| Strategy | Efficiency ratio (Δ COL / Δ CRC deaths averted) | ||
|---|---|---|---|
| SimCRC | CRC-SPIN | MISCAN | |
| SIG 55-70, 10 | -- | -- | -- |
| SIG 55-75, 10 | 77* | 103 | 89 |
| SIG 50-70, 10 | 70 | 122 | 419* |
| SIG 45-70, 10 | 89* | 301* | Dominated |
| SIG 55-85, 10 | 93* | 226* | 184* |
| SIG 55-70, 5 | 313* | 460* | 207* |
| SIG 50-80, 10 | 110* | 154* | 151* |
| SIG 55-75, 5 | 146* | 448* | 149* |
| SIG 45-75, 10 | 106 | 125 | 245* |
| SIG 50-70, 5 | 1415* | 220* | 221* |
| SIG 45-85, 10 | 185* | 252 | 229* |
| SIG 55-80, 5 | 151* | Dominated | 148 |
| SIG 55-85, 5 | Dominated | Dominated | 301* |
| SIG 50-75, 5 | 153* | 194* | 350* |
| SIG 45-70, 5 | 171* | 2946* | Dominated |
| SIG 50-80, 5 | 156* | 726* | 235 |
| SIG 50-85, 5 | 170* | 1530* | 294 |
| SIG 45-75, 5 | 144 | 323* | 395* |
| SIG 45-80, 5 | 171 | 294 | 500* |
| SIG 45-85, 5 | 297 | 396 | 440 |
COL – colonoscopy; CRC – colorectal cancer; SIG – sigmoidoscopy; -- indicates the default strategy (i.e., the strategy requiring the fewest colonoscopies and averting the fewest colorectal cancer deaths).
Near efficient (i.e., within 0.75 colorectal cancer deaths averted per 1000 of the efficient frontier).
Note: Strategies that were dominated in all 3 models are not shown. Analyses assume an increased population risk of colorectal cancer based on an incidence rate ratio comparing colorectal cancer incidence among 20- to 44-year-olds in 2012-2016 vs 1975-1979 of 1.19.
| Strategy | Efficiency ratio (Δ COL / Δ CRC deaths averted) | ||
|---|---|---|---|
| SimCRC | CRC-SPIN | MISCAN | |
| SIG+FIT 55-70, 10_2 | -- | -- | -- |
| SIG+FIT 55-70, 10_1 | Dominated | 189* | 162* |
| SIG+FIT 55-75, 10_2 | 91 | 135 | 89* |
| SIG+FIT 50-70, 10_2 | 101* | 159* | Dominated |
| SIG+FIT 55-80, 10_2 | 112* | 158* | 88 |
| SIG+FIT 50-75, 10_2 | 94 | 148 | 1234* |
| SIG+FIT 45-70, 10_2 | Dominated | 337* | Dominated |
| SIG+FIT 55-85, 10_2 | 161* | 207* | 162 |
| SIG+FIT 55-75, 10_1 | Dominated | 279* | 438* |
| SIG+FIT 50-70, 10_1 | Dominated | 458* | Dominated |
| SIG+FIT 50-80, 10_2 | 131 | 179* | 195* |
| SIG+FIT 55-80, 10_1 | Dominated | 156027* | 405* |
| SIG+FIT 50-85, 10_2 | 179* | 186* | 183 |
| SIG+FIT 45-75, 10_2 | 170* | 169* | 475* |
| SIG+FIT 55-85, 10_1 | Dominated | Dominated | 258* |
| SIG+FIT 50-75, 10_1 | Dominated | 271* | 634* |
| SIG+FIT 45-80, 10_2 | 147 | 168 | 342* |
| SIG+FIT 45-70, 10_1 | Dominated | 286* | Dominated |
| SIG+FIT 50-80, 10_1 | Dominated | 262* | 369* |
| SIG+FIT 45-85, 10_2 | 211 | 290 | 476* |
| SIG+FIT 50-85, 10_1 | 336* | 275* | 312 |
| SIG+FIT 45-75, 10_1 | 950* | 1456* | 1256* |
| SIG+FIT 45-80, 10_1 | 658* | 504* | 3232* |
| SIG+FIT 45-85, 10_1 | 488 | 455 | 522 |
COL – colonoscopy; CRC – colorectal cancer; SIG – sigmoidoscopy; FIT – fecal immunochemical test with a cutoff for positivity of 20 μg of hemoglobin per g of feces; -- indicates the default strategy (i.e., the strategy requiring the fewest colonoscopies and averting the fewest colorectal cancer deaths).
Near efficient (i.e., within 0.75 colorectal cancer deaths averted per 1000 of the efficient frontier).
Note: Strategies that were dominated in all 3 models are not shown. Analyses assume an increased population risk of colorectal cancer based on an incidence rate ratio comparing colorectal cancer incidence among 20- to 44-year-olds in 2012-2016 vs 1975-1979 of 1.19.
| Strategy | Efficiency ratio (Δ COL / Δ CRC deaths averted) | ||
|---|---|---|---|
| SimCRC | CRC-SPIN | MISCAN | |
| CTC 55-70, 10 | -- | -- | -- |
| CTC 55-75, 10 | 74* | 90 | 45 |
| CTC 50-70, 10 | 64 | 209* | Dominated |
| CTC 45-70, 10 | Dominated | 113* | Dominated |
| CTC 55-70, 5 | Dominated | 240* | 587* |
| CTC 55-85, 10 | Dominated | 188* | 77 |
| CTC 50-80, 10 | 107* | 127* | 78* |
| CTC 55-75, 5 | Dominated | 161* | 83* |
| CTC 45-75, 10 | 105 | 114 | Dominated |
| CTC 50-70, 5 | 151* | 156* | Dominated |
| CTC 55-80, 5 | Dominated | 167* | 78 |
| CTC 45-85, 10 | 186* | 182 | Dominated |
| CTC 55-85, 5 | Dominated | 178* | 116 |
| CTC 50-75, 5 | 207* | 549* | Dominated |
| CTC 45-70, 5 | 276* | 483* | Dominated |
| CTC 50-80, 5 | 193* | 266* | 212* |
| CTC 50-85, 5 | 207* | 267* | 171 |
| CTC 45-75, 5 | 169* | 210* | Dominated |
| CTC 45-80, 5 | 169 | 202 | 1355* |
| CTC 45-85, 5 | 324 | 281 | 325 |
COL – colonoscopy; CRC – colorectal cancer; CTC – computed tomographic colonography; -- indicates the default strategy (i.e., the strategy requiring the fewest colonoscopies and averting the fewest colorectal cancer deaths).
Near efficient (i.e., within 0.75 colorectal cancer deaths averted per 1000 of the efficient frontier).
Note: Strategies that were dominated in all 3 models are not shown. Analyses assume an increased population risk of colorectal cancer based on an incidence rate ratio comparing colorectal cancer incidence among 20- to 44-year-olds in 2012-2016 vs 1975-1979 of 1.19.